Effect of dopamine agonists on fatigue and somnolence in Parkinson's disease
Identifieur interne : 001315 ( Main/Exploration ); précédent : 001314; suivant : 001316Effect of dopamine agonists on fatigue and somnolence in Parkinson's disease
Auteurs : Daniel Oved [Israël] ; Ilan Ziv [Israël] ; Therese A. Treves [Israël] ; Diana Paleacu [Israël] ; Eldad Melamed [Israël] ; Ruth Djaldetti [Israël]Source :
- Movement Disorders [ 0885-3185 ] ; 2006-08.
English descriptors
Abstract
Dopamine agonists are becoming increasingly important in the treatment of early and advanced symptoms of Parkinson disease (PD). Although dopamine agonists are known to increase somnolence, their effect on fatigue and the relationship between fatigue and somnolence have not been investigated thoroughly. The objective of this study is to quantitatively measure fatigue in patients with PD treated with dopamine agonists and to correlate fatigue with somnolence. Fifteen patients with PD (mean age, 60.6 ± 9.7 years; mean disease duration, 4.1 ± 1.9 years) underwent a continuous (30‐second) motor task using four muscle groups before and after 3 months of treatment with dopamine agonists. A fatigue index, defined as the decay of maximal force during continuous exercise, was calculated. Findings were compared with 15 healthy, age‐matched control subjects. Patients also completed the Multidimensional Fatigue Inventory (MFI), the Epworth Sleepiness Scale (ESS), and the Hamilton Depression Scale at the same time points. Mean fatigue index (FI) before treatment was significantly higher in PD patients than controls (31.37% ± 3.81% vs. 23.39% ± 3.03%, P < 0.001). There was no significant between‐group difference after 3 months of treatment. There was no difference in FI of the more affected side before and after treatment (33.33% ± 6.18% vs. 34.08% ± 5.43%, P > 0.1). No significant change in MFI scores were noted after treatment, although scores on the ESS increased significantly (6.6 ± 2.63 vs. 11.7 ± 5.16; P < 0.05). Fatigue is prevalent in patients with PD but is not influenced by dopamine agonists. Somnolence cannot be attributed to the increase in fatigability and apparently involves a different mechanism. © 2006 Movement Disorder Society
Url:
DOI: 10.1002/mds.20929
Affiliations:
Links toward previous steps (curation, corpus...)
Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Effect of dopamine agonists on fatigue and somnolence in Parkinson's disease</title><author><name sortKey="Oved, Daniel" sort="Oved, Daniel" uniqKey="Oved D" first="Daniel" last="Oved">Daniel Oved</name></author><author><name sortKey="Ziv, Ilan" sort="Ziv, Ilan" uniqKey="Ziv I" first="Ilan" last="Ziv">Ilan Ziv</name></author><author><name sortKey="Treves, Therese A" sort="Treves, Therese A" uniqKey="Treves T" first="Therese A." last="Treves">Therese A. Treves</name></author><author><name sortKey="Paleacu, Diana" sort="Paleacu, Diana" uniqKey="Paleacu D" first="Diana" last="Paleacu">Diana Paleacu</name></author><author><name sortKey="Melamed, Eldad" sort="Melamed, Eldad" uniqKey="Melamed E" first="Eldad" last="Melamed">Eldad Melamed</name></author><author><name sortKey="Djaldetti, Ruth" sort="Djaldetti, Ruth" uniqKey="Djaldetti R" first="Ruth" last="Djaldetti">Ruth Djaldetti</name></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:3D2024886689A4FFEFC2A1653A88BC5959151454</idno><date when="2006" year="2006">2006</date><idno type="doi">10.1002/mds.20929</idno><idno type="url">https://api.istex.fr/document/3D2024886689A4FFEFC2A1653A88BC5959151454/fulltext/pdf</idno><idno type="wicri:Area/Main/Corpus">000A73</idno><idno type="wicri:Area/Main/Curation">000937</idno><idno type="wicri:Area/Main/Exploration">001315</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Effect of dopamine agonists on fatigue and somnolence in Parkinson's disease</title><author><name sortKey="Oved, Daniel" sort="Oved, Daniel" uniqKey="Oved D" first="Daniel" last="Oved">Daniel Oved</name><affiliation wicri:level="1"><country xml:lang="fr">Israël</country><wicri:regionArea>Department of Neurology, Rabin Medical Center, Beilinson Campus, Petah Tiqwa</wicri:regionArea><wicri:noRegion>Petah Tiqwa</wicri:noRegion></affiliation></author><author><name sortKey="Ziv, Ilan" sort="Ziv, Ilan" uniqKey="Ziv I" first="Ilan" last="Ziv">Ilan Ziv</name><affiliation wicri:level="1"><country xml:lang="fr">Israël</country><wicri:regionArea>Department of Neurology, Rabin Medical Center, Beilinson Campus, Petah Tiqwa</wicri:regionArea><wicri:noRegion>Petah Tiqwa</wicri:noRegion></affiliation></author><author><name sortKey="Treves, Therese A" sort="Treves, Therese A" uniqKey="Treves T" first="Therese A." last="Treves">Therese A. Treves</name><affiliation wicri:level="1"><country xml:lang="fr">Israël</country><wicri:regionArea>Department of Neurology, Rabin Medical Center, Beilinson Campus, Petah Tiqwa</wicri:regionArea><wicri:noRegion>Petah Tiqwa</wicri:noRegion></affiliation></author><author><name sortKey="Paleacu, Diana" sort="Paleacu, Diana" uniqKey="Paleacu D" first="Diana" last="Paleacu">Diana Paleacu</name><affiliation wicri:level="1"><country xml:lang="fr">Israël</country><wicri:regionArea>Neurology Service and Memory Clinic, Abarbanel Mental Health Center, Bat Yam</wicri:regionArea><wicri:noRegion>Bat Yam</wicri:noRegion></affiliation></author><author><name sortKey="Melamed, Eldad" sort="Melamed, Eldad" uniqKey="Melamed E" first="Eldad" last="Melamed">Eldad Melamed</name><affiliation wicri:level="1"><country xml:lang="fr">Israël</country><wicri:regionArea>Department of Neurology, Rabin Medical Center, Beilinson Campus, Petah Tiqwa</wicri:regionArea><wicri:noRegion>Petah Tiqwa</wicri:noRegion></affiliation></author><author><name sortKey="Djaldetti, Ruth" sort="Djaldetti, Ruth" uniqKey="Djaldetti R" first="Ruth" last="Djaldetti">Ruth Djaldetti</name><affiliation wicri:level="1"><country xml:lang="fr">Israël</country><wicri:regionArea>Department of Neurology, Rabin Medical Center, Beilinson Campus, Petah Tiqwa</wicri:regionArea><wicri:noRegion>Petah Tiqwa</wicri:noRegion></affiliation></author></analytic><monogr></monogr><series><title level="j">Movement Disorders</title><title level="j" type="sub">Official Journal of the Movement Disorder Society</title><title level="j" type="abbrev">Mov. Disord.</title><idno type="ISSN">0885-3185</idno><idno type="eISSN">1531-8257</idno><imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>Hoboken</pubPlace><date type="published" when="2006-08">2006-08</date><biblScope unit="volume">21</biblScope><biblScope unit="issue">8</biblScope><biblScope unit="page" from="1257">1257</biblScope><biblScope unit="page" to="1261">1261</biblScope></imprint><idno type="ISSN">0885-3185</idno></series><idno type="istex">3D2024886689A4FFEFC2A1653A88BC5959151454</idno><idno type="DOI">10.1002/mds.20929</idno><idno type="ArticleID">MDS20929</idno></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0885-3185</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>dopamine agonists</term><term>fatigue</term><term>somnolence, Parkinson's disease</term></keywords></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Dopamine agonists are becoming increasingly important in the treatment of early and advanced symptoms of Parkinson disease (PD). Although dopamine agonists are known to increase somnolence, their effect on fatigue and the relationship between fatigue and somnolence have not been investigated thoroughly. The objective of this study is to quantitatively measure fatigue in patients with PD treated with dopamine agonists and to correlate fatigue with somnolence. Fifteen patients with PD (mean age, 60.6 ± 9.7 years; mean disease duration, 4.1 ± 1.9 years) underwent a continuous (30‐second) motor task using four muscle groups before and after 3 months of treatment with dopamine agonists. A fatigue index, defined as the decay of maximal force during continuous exercise, was calculated. Findings were compared with 15 healthy, age‐matched control subjects. Patients also completed the Multidimensional Fatigue Inventory (MFI), the Epworth Sleepiness Scale (ESS), and the Hamilton Depression Scale at the same time points. Mean fatigue index (FI) before treatment was significantly higher in PD patients than controls (31.37% ± 3.81% vs. 23.39% ± 3.03%, P < 0.001). There was no significant between‐group difference after 3 months of treatment. There was no difference in FI of the more affected side before and after treatment (33.33% ± 6.18% vs. 34.08% ± 5.43%, P > 0.1). No significant change in MFI scores were noted after treatment, although scores on the ESS increased significantly (6.6 ± 2.63 vs. 11.7 ± 5.16; P < 0.05). Fatigue is prevalent in patients with PD but is not influenced by dopamine agonists. Somnolence cannot be attributed to the increase in fatigability and apparently involves a different mechanism. © 2006 Movement Disorder Society</div></front></TEI><affiliations><list><country><li>Israël</li></country></list><tree><country name="Israël"><noRegion><name sortKey="Oved, Daniel" sort="Oved, Daniel" uniqKey="Oved D" first="Daniel" last="Oved">Daniel Oved</name></noRegion><name sortKey="Djaldetti, Ruth" sort="Djaldetti, Ruth" uniqKey="Djaldetti R" first="Ruth" last="Djaldetti">Ruth Djaldetti</name><name sortKey="Melamed, Eldad" sort="Melamed, Eldad" uniqKey="Melamed E" first="Eldad" last="Melamed">Eldad Melamed</name><name sortKey="Paleacu, Diana" sort="Paleacu, Diana" uniqKey="Paleacu D" first="Diana" last="Paleacu">Diana Paleacu</name><name sortKey="Treves, Therese A" sort="Treves, Therese A" uniqKey="Treves T" first="Therese A." last="Treves">Therese A. Treves</name><name sortKey="Ziv, Ilan" sort="Ziv, Ilan" uniqKey="Ziv I" first="Ilan" last="Ziv">Ilan Ziv</name></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/ParkinsonV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001315 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 001315 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= ParkinsonV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= ISTEX:3D2024886689A4FFEFC2A1653A88BC5959151454
|texte= Effect of dopamine agonists on fatigue and somnolence in Parkinson's disease
}}
| This area was generated with Dilib version V0.6.23. |  |